Track and Trace Battle Looms At Senate User Fee Mark-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Sens. Bennet and Burr file amendment to implement the industry-backed RxTEC proposal, which would require serialization, but is not a full track-and-trace system and is not supported by FDA.
You may also be interested in...
User Fee Bills: After Mark-ups, How Will House And Senate Reconcile Differences?
House and Senate committee user fee bill mark-ups approaching, but drafts have differences in drug shortage, supply chain security and other proposed policy changes to reconcile.
GMP Third-Party Audits Offered In Draft Senate User Fee Legislation
Bipartisan group of senators unveils several draft provisions of user fee legislation, including a program to allow third-party auditors to evaluate manufacturing facility compliance with U.S. standards for drugs.
Supply Chain Safety’s Dual Visions: Pedigree Or Just Serialization
As Congress considers how to ensure downstream supply chain security, industry groups are looking at a process to link drugs to their manufacturer. But in a recent communication with the Senate HELP Committee, FDA backs a “comprehensive national track-and-trace system.”